FR15C0033I2 - Support macromoleculaire sur base de dextran pour l'administration d'un agent diagnostique ou therapeutique - Google Patents

Support macromoleculaire sur base de dextran pour l'administration d'un agent diagnostique ou therapeutique

Info

Publication number
FR15C0033I2
FR15C0033I2 FR15C0033C FR15C0033C FR15C0033I2 FR 15C0033 I2 FR15C0033 I2 FR 15C0033I2 FR 15C0033 C FR15C0033 C FR 15C0033C FR 15C0033 C FR15C0033 C FR 15C0033C FR 15C0033 I2 FR15C0033 I2 FR 15C0033I2
Authority
FR
France
Prior art keywords
diagnostic
dextran
administration
therapeutic agent
support based
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR15C0033C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regents Of Univ Of
University of Michigan Ann Arbor
Original Assignee
Regents Of Univ Of
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regents Of Univ Of, University of Michigan Ann Arbor filed Critical Regents Of Univ Of
Publication of FR15C0033I1 publication Critical patent/FR15C0033I1/fr
Application granted granted Critical
Publication of FR15C0033I2 publication Critical patent/FR15C0033I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
    • A61K49/128—Linear polymers, e.g. dextran, inulin, PEG comprising multiple complex or complex-forming groups, being either part of the linear polymeric backbone or being pending groups covalently linked to the linear polymeric backbone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/50—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications
    • A61B6/508—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment specially adapted for specific body parts; specially adapted for specific clinical applications for non-human patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dentistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
FR15C0033C 1999-05-14 2015-04-23 Support macromoleculaire sur base de dextran pour l'administration d'un agent diagnostique ou therapeutique Active FR15C0033I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13432999P 1999-05-14 1999-05-14
PCT/US2000/013300 WO2000069473A2 (en) 1999-05-14 2000-05-12 Macromolecular carrier for drug and diagnostic agent delivery

Publications (2)

Publication Number Publication Date
FR15C0033I1 FR15C0033I1 (de) 2015-06-26
FR15C0033I2 true FR15C0033I2 (fr) 2016-09-09

Family

ID=22462862

Family Applications (1)

Application Number Title Priority Date Filing Date
FR15C0033C Active FR15C0033I2 (fr) 1999-05-14 2015-04-23 Support macromoleculaire sur base de dextran pour l'administration d'un agent diagnostique ou therapeutique

Country Status (10)

Country Link
US (1) US6409990B1 (de)
EP (1) EP1178838B1 (de)
JP (2) JP4056701B2 (de)
AT (1) ATE277642T1 (de)
AU (1) AU5270500A (de)
DE (1) DE60014359T2 (de)
ES (1) ES2228536T3 (de)
FR (1) FR15C0033I2 (de)
NL (1) NL300736I2 (de)
WO (1) WO2000069473A2 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770261B2 (en) * 1995-06-02 2004-08-03 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
AU752812B2 (en) 1997-11-17 2002-10-03 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the detection of physiological agents
ATE277642T1 (de) * 1999-05-14 2004-10-15 Univ California Makromolekular träger auf basis von dextran fur arzneimittel und diagnosticum abgabe
US20040146463A1 (en) * 2000-05-04 2004-07-29 Meade Thomas J. Functional MRI agents for cancer imaging
US6673333B1 (en) * 2000-05-04 2004-01-06 Research Corporation Technologies, Inc. Functional MRI agents for cancer imaging
WO2002043771A2 (en) 2000-12-01 2002-06-06 Cell Works Inc. Conjugates of glycosylated/galactosylated peptide
US20030004236A1 (en) * 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
US20020197648A1 (en) * 2001-05-02 2002-12-26 Silva Robin M. High throughput screening methods using magnetic resonance imaging agents
WO2003057715A2 (en) * 2001-12-28 2003-07-17 The Regents Of The University Of California Novel ligand involved in the transmigration of leukocytes .
US20030198597A1 (en) * 2002-04-22 2003-10-23 Meade Thomas J. Novel macrocyclic activatible magnetic resonance imaging contrast agents
US7651689B2 (en) * 2002-11-15 2010-01-26 Albert Einstein College Of Medicine Of Yeshiva University Methods of applying ionization radiation for therapy of infections
AU2004209644A1 (en) * 2003-02-03 2004-08-19 Palo Alto Institute Of Molecular Medicine Cell-killing molecules and methods of use thereof
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20050171424A1 (en) * 2004-01-13 2005-08-04 The Gov. Of The Usa As Rep. By The Secretary Of The Dept. Of Health And Human Services Methods for imaging the lymphatic system using dendrimer-based contrast agents
US20050186642A1 (en) 2004-02-24 2005-08-25 Biocare Medical, Inc. Immunoassay reagents and methods of use thereof
JPWO2005117995A1 (ja) * 2004-06-03 2008-04-03 丈二 北山 ヒアルロン酸のセンチネルリンパ節同定への応用
US7381400B2 (en) * 2004-07-13 2008-06-03 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Injection of a radioactive dye for sentinel lymph node identification
US20060204443A1 (en) * 2005-03-11 2006-09-14 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for tumor treatment using dendrimer conjugates
DE102005018330B4 (de) 2005-04-20 2007-04-19 Siemens Ag System zur Erzeugung von CT-Bilddatensätzen und zur Bestrahlung eines Tumor-Patienten
JP4934802B2 (ja) * 2005-05-30 2012-05-23 国立大学法人信州大学 リンパ系の細胞接着物質、リンパ系薬物輸送材およびそれを含有する薬剤
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
WO2008022263A2 (en) * 2006-08-17 2008-02-21 Epix Pharmaceuticals, Inc. Methods for lymph system imaging
US20100196272A1 (en) * 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
WO2012027493A1 (en) 2010-08-24 2012-03-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Molecular imaging of cancer cells in vivo
WO2012154983A2 (en) 2011-05-10 2012-11-15 Biocare Medical, Llc Systems and methods for anti-pax8 antibodies
US10316103B1 (en) 2012-03-30 2019-06-11 Biocare Medical, Llc Systems and methods for anti-Uroplakin III antibodies
ES2682345T3 (es) 2012-09-27 2018-09-20 Biocare Medical, Llc Sistemas y procedimientos de anticuerpos antiuroplaquina II
WO2014100220A2 (en) 2012-12-18 2014-06-26 Biocare Medical, Llc Antibody cocktail systems and methods for classification of histologic subtypes in lung cancer
EP2962113B1 (de) 2013-02-28 2019-04-03 Biocare Medical, LLC Systeme und verfahren mit anti-pd40-antikörpern
JP6163698B2 (ja) * 2013-03-21 2017-07-19 国立大学法人 千葉大学 マクロファージマンノース受容体を認識する新規多糖金属錯体化合物、及び、その医薬組成物
EP3024493A1 (de) * 2013-07-22 2016-06-01 Navidea Biopharmaceuticals, Inc. Zusammensetzungen, verfahren und kits zur diagnose und behandlung von durch cd206-exprimierende zellen vermittelte erkrankungen
CN104511030A (zh) * 2013-09-29 2015-04-15 复旦大学 基于葡聚糖的双模态纳米影像药物-Dex-Rho-99mTc
ES2765423T3 (es) 2013-10-03 2020-06-09 Biocare Medical Llc Sistemas y procedimientos de anticuerpos anti-SOX10
US10328149B2 (en) 2014-06-13 2019-06-25 Tenboron Oy Conjugates comprising an anti-EGFR1 antibody
EP3169336A4 (de) * 2014-07-17 2018-04-04 Ohio State Innovation Foundation Zusammensetzungen zum targeting von makrophagen und anderen cd206-hochexprimierenden zellen sowie verfahren zur behandlung und diagnose
CA2955438C (en) * 2014-07-17 2024-07-02 Ohio State Innovation Foundation DEXTRANE CONJUGATES TO TARGET MACROPHAGES AND OTHER CELLS EXPRESSING THE D-MANBOSE BINDING TYPE C LECTIN RECEPTOR
US10806803B2 (en) * 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
US20160206763A1 (en) * 2015-01-21 2016-07-21 Navidea Biopharmaceuticals, Inc. Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
CN106317237B (zh) * 2015-07-03 2019-07-19 华中科技大学 一种用于spect成像的当归多糖衍生物及其合成方法
CA2999975A1 (en) * 2015-09-25 2017-03-30 Serene, Llc Sn-117m labeled mannose coupled dextran amine
WO2017062420A1 (en) 2015-10-05 2017-04-13 Serene, Llc Hyaluronan sn-117m colloid for radiosynoviorthersis and symptomatic therapy related applications
US20180092998A1 (en) * 2016-10-04 2018-04-05 Cardinal Health, 414 Llc Compositions and methods for diagnosing and treating macrophage-related disorders using carbohydrate-based macromolecular carrier
IL265846B2 (en) * 2016-10-07 2024-02-01 Navidea Biopharmaceuticals Inc Compounds and methods for diagnosis and treatment of viral infections
JP6329302B2 (ja) * 2017-05-10 2018-05-23 国立大学法人千葉大学 マクロファージマンノース受容体を認識する新規多糖金属錯体化合物、及び、その医薬組成物
CN114555131A (zh) * 2019-08-19 2022-05-27 纳维迪亚生物制药有限公司 用于消融m2巨噬细胞和髓源性抑制细胞的组合物和相关方法
JP7599727B2 (ja) * 2019-09-30 2024-12-16 ナビディア、バイオファーマスーティカルズ、インコーポレイテッド マンノシル化デキストラン治療用または診断用化合物の標的特異性を高めるためのキット
US12070504B1 (en) 2020-07-01 2024-08-27 Physis International LLC Compounds and methods for altering cyto-states of cells that express c-type lectin receptors
US11497763B1 (en) 2020-07-01 2022-11-15 Physis International LLC Compounds and methods for treating and diagnosing RNA virus infections
CA3168879A1 (en) * 2020-07-08 2022-01-13 Navidea Biopharmaceuticals, Inc. Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof
MX2023002038A (es) * 2020-08-21 2023-05-08 Resolute Science Inc Composiciones y metodos para dirigirse a macrofagos asociados a tumor.
US11833170B2 (en) * 2022-02-04 2023-12-05 Navidea Biopharmaceuticals, Inc. Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
WO2023183922A2 (en) * 2022-03-25 2023-09-28 Navidea Biopharmaceuticals, Inc. Competitive self-blocking with unlabeled manocept imaging agents
JP2025535006A (ja) * 2022-10-03 2025-10-22 ナビディア、バイオファーマスーティカルズ、インコーポレイテッド 炭水化物ポリマーに結合されたアミン終端リーシュへの糖部分のアミド結合

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE286598C (de)
US4707440A (en) * 1984-01-30 1987-11-17 Enzo Biochem, Inc. Nucleic acid hybridization assay and detectable molecules useful in such assay
US5175269A (en) * 1984-01-30 1992-12-29 Enzo Diagnostics, Inc. Compound and detectable molecules having an oligo- or polynucleotide with modifiable reactive group
SE465907B (sv) * 1984-11-01 1991-11-18 Nyegaard & Co As Diagnosticeringsmedel innehaallande en paramagnetisk metall
US5336762A (en) * 1985-11-18 1994-08-09 Access Pharmaceuticals, Inc. Polychelating agents for image and spectral enhancement (and spectral shift)
US5490991A (en) * 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
US4822594A (en) * 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
CS263561B1 (en) * 1987-09-18 1989-04-14 Kery Vladimir Process for preparing water soluble allylderivatives of oligo and polysaccharides
DD286598A5 (de) * 1989-06-29 1991-01-31 Adw Der Ddr,Zi F. Mulekularbiologie,De Verfahren zur einfuehrung von primaeren aminogruppen in wasserloesliche polymere
US5789578A (en) * 1996-01-11 1998-08-04 Massey University Methods for the preparation of resins with ligands attached thereto through a linking group comprising sulfide, sulfoxide or sulfone functionality
WO1998018497A2 (en) * 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
WO1998023293A1 (en) * 1996-11-28 1998-06-04 Nihon Schering K.K. Contrast compound, contrast medium for mri, and method for mri
ATE277642T1 (de) * 1999-05-14 2004-10-15 Univ California Makromolekular träger auf basis von dextran fur arzneimittel und diagnosticum abgabe

Also Published As

Publication number Publication date
EP1178838B1 (de) 2004-09-29
US6409990B1 (en) 2002-06-25
NL300736I1 (de) 2016-01-26
EP1178838A2 (de) 2002-02-13
NL300736I2 (de) 2016-01-26
WO2000069473A2 (en) 2000-11-23
JP2007332380A (ja) 2007-12-27
JP2002544243A (ja) 2002-12-24
FR15C0033I1 (de) 2015-06-26
WO2000069473A3 (en) 2001-08-16
ATE277642T1 (de) 2004-10-15
JP4056701B2 (ja) 2008-03-05
AU5270500A (en) 2000-12-05
DE60014359T2 (de) 2006-02-23
DE60014359D1 (de) 2004-11-04
ES2228536T3 (es) 2005-04-16

Similar Documents

Publication Publication Date Title
NL300736I1 (de)
DZ2887A1 (fr) Dérivés d'azétidine, leur préparation et les médicaments les contenant.
BR0014652A (pt) Fabricação de conjugados de agente terapêutico-poliglutamato
AR244998A1 (es) Dispositivo para obtener y administrar agentes de contraste, basadosen microburbujas, para ecos ultrasonicos.
ES2075468T3 (es) Vehiculos de suministro de farmacos suspendidos en un portador perfluorado no acuoso.
NO175364C (no) Fysiologisk forenlige amidkomplekser, diagnostiske midler og anvendelse derav
FR2659856B1 (fr) Pompe portable d'administration d'une substance therapeutique liquide.
ATE177657T1 (de) Intravaginales wirkstoffabgabesystem
NL190508B (nl) Preparaat geschikt voor gebruik als matrix in een systeem voor het toedienen van een geneesmiddel, alsmede een transdermaal therapeutisch systeem, dat het preparaat omvat.
DE69011059D1 (de) Heterozyklische Acylaminothiazolderivate, ihre Herstellung und diese enthaltende pharmazeutische Zubereitungen.
NO980002D0 (no) Kaskadepolymerkomplekser, fremgangsmåte for fremstilling, samt farmasöytiske midler inneholdende disse
IT8485554A0 (it) Sacca contenente due o piu'sostanze per infusione ad uso medicale, poste in scomparti separati, comprendente mezzi atti a consentire la miscelazione di tali sostanze solo al momento dell'uso.
MA21264A1 (fr) Composition permettant d'administrer un medicament sous forme de gellules, d'une poudre ou d'un liquide.
EE200100179A (et) Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks
NO880179D0 (no) Polymerkomplekser, fremgangsmaate for fremstilling av disse, og farmasoeytiske midler inneholdende disse.
FR2781154B1 (fr) Composition therapeutique a base d'isoflavonoides destinee a etre utilisee dans le traitement des tumeurs par des agents cytotoxiques
FI874166A7 (fi) 2',3'-dideoksisytidin-2'-eenin käyttö retroviruksilla infektoituneiden potilaiden hoitoon.
RU94002476A (ru) Лекарственное средство
SE9601659D0 (sv) Diagnostisk läkemedelsberedning
ATE249243T1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
Kazakov et al. Some biochemical bases of adverse reactions to antibacterial drugs in nephrophthisis and ways for their elimination.
IT1248486B (it) Agente terapeutico ad attivita' sul sistema nervoso centrale
ATA263487A (de) Neue verbindungen, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
Follies et al. What bugs you about nursing practice.
EP0297117A4 (de) Biologisch aktives mittel.